ライフサイエンスコーパス: B-cell leukemia

1 innate immunity to virally induced acute pro-B cell leukemia.

2 ed by the t(1;19) translocation in human pre-B cell leukemia.

3 nd correlate these networks with subtypes of B cell leukemia.

4 nized anti-CD22 mAb having been used against B cell leukemia.

5 re-BCR) signaling, spontaneously develop pre-B cell leukemia.

6 therapy for relapsed or refractory pediatric B cell leukemia.

7 s well as in a subset of patients with acute B-cell leukemia.

8 gens have been studied for the management of B-cell leukemia.

9 x and mEg5 contributes to the development of B-cell leukemia.

10 oncogene product, v-Abl, and also causes pre-B-cell leukemia.

11 manner in a Nalm-6 xenograft rodent model of B-cell leukemia.

12 ients with lymphoma than in those with acute B-cell leukemia.

13 of miR-125b in mice can promote myeloid and B-cell leukemia.

14 mplying a role in the pathogenesis of mature B-cell leukemia.

15 favorable outcome in patients with precursor B-cell leukemia.

16 with peripheral blood eosinophila and T- or B-cell leukemias.

17 of the IL-2R in T-cell leukemias and p75 in B-cell leukemias.

18 the most frequent genetic alteration in AKXD B-cell leukemias.

19 plicated in the development of childhood pre-B-cell leukemias.

20 not been detected in patients with human pre-B-cell leukemias.

21 patients with autoimmune diseases or various B-cell leukemias.

22 ibition as a potential therapeutic target in B-cell leukemias.

23 they up-regulated the antiapoptotic protein B-cell leukemia 2 (Bcl-2) by 10-fold.

24 ld down-regulated in MCL; in addition to the B-cell leukemia 2 (BCL2) system other apoptotic pathways

25 duced expression of the proapoptotic protein B-cell leukemia 2 homology 3 (BH3) interacting domain de

26 leukemia sequence-1 (MCL1), an antiapoptotic B cell leukemia-2 family member.

27 ia-1 (Mcl-1), an antiapoptotic member of the B-cell leukemia-2 family, is an important participant in

28 enotype (35%) or a lethal, short-latency pre-B-cell leukemia (20%).

29 B cell leukemia 3 (Bcl-3) is an essential negative regul

30 Lipopolysaccharide (LPS)-induced B cell leukemia 3 (Bcl3) expression was strongly impaire

31 on of NR4A1 and NR4A3 in chronic lymphocytic B-cell leukemia (71%), in follicular lymphoma (FL, 70%),

32 y HIT receptors in xenograft mouse models of B cell leukemia and acute myeloid leukemia, targeting CD

33 9 have led to remarkable clinical results in B cell leukemia and lymphoma but eliminate all B lineage

34 Substantial numbers of B cell leukemia and lymphoma patients relapse due to ant

35 ing to driver mutations found recurrently in B cell leukemia and lymphoma.

36 ly for multiple myeloma, but also for mature B cell leukemia and lymphoma.

37 eficiency strongly suppressed Emu-Myc-driven B cell leukemia and the antiapoptotic effects of Emu-BCL

38 Clinical trials in patients with advanced B cell leukemias and lymphomas treated with CD19-specifi

39 vailability of life-extending treatments for B cell leukemias and lymphomas, many of these cancers re

40 eving remarkable remissions in patients with B cell leukemias and lymphomas.

41 impressive results in treating patients with B cell leukemias and lymphomas.

42 inical concepts to target the BCR pathway in B-cell leukemia and lymphoma.

43 n younger than 6 years of age with precursor B-cell leukemia and no adverse genetic features had a 10

44 for the epigenetic changes that occur in pre-B-cell leukemia and other B-cell-related diseases.

45 chieved impressive clinical outcomes in some B-cell leukemias and lymphomas but not in AML.

46 th c-MYC and delays the generation of T- and B-cell leukemias and lymphomas.

47 ed from the bone marrow of patients with pre-B-cell leukemias and these findings should facilitate th

48 AR) design that simultaneously targets three B cell leukemia antigens.

49 We report the identification of B cell leukemia (Bcl)-3 as an essential negative regulat

50 nd modulated by virus-encoded anti-apoptotic B cell leukemia (BCL)2-like suppressors.

51 We report here the identification of B-cell leukemia (Bcl)-3 as a modulator of innate immune

52 monstrated that miR-125b induces myeloid and B-cell leukemia by inhibiting interferon regulatory fact

53 model for an inducible and reversible acute B-cell leukemia caused by p210 BCR/ABL.

54 In this study, we show that B cell leukemia causes T cells to become activated and h

55 Earlier work with the DT40 chicken B cell leukemia cell line showed that Syk was required t

56 pment, and is expressed in a number of human B cell leukemia cell lines, primary human chronic myeloi

57 HC II expression restrained growth of murine B-cell leukemia cell lines in vitro and in vivo, indepen

58 ute promyelocytic leukemia (APL) and chronic B-cell leukemia cell lines, respectively.

59 In human B cell leukemia cells, binding of wild-type PAX5 to a re

60 cts of RAR and RXR rexinoids in human T- and B-cell leukemia cells and demonstrated that RXR rexinoid

61 In pre B cell leukemias containing the t(1;19) chromosome trans

62 AX5-ETV6 as a potent oncoprotein that drives B-cell leukemia development.

63 across all subgroups of B-cell lymphomas and B-cell leukemias, establishing CD22 as a valuable immuno

64 Pre-B cell leukemia factor 1 (PBX1) is an essential developm

65 Here, we explored pre-B cell leukemia homeobox 1 (PBX1) in adult neurogenesis

66 Pre-B cell leukemia homeobox 1 (Pbx1)-d is a dominant-negati

67 Pre-B-cell leukemia homeobox (PBX) and myeloid ecotropic vir

68 Pre-B-cell leukemia homeobox (PBX) transcription factors are

69 Pre-B-cell leukemia homeobox (Pbx)-regulating protein-1 (Pre

70 otein (PBXIP1/HPIP) is a co-repressor of pre-B-cell leukemia homeobox 1 (PBX1) and is also known to r

71 id ecotropic viral integration 1 (Meis1)/pre-B-cell leukemia homeobox 3 (Pbx3) genes.

72 Pre-B-cell leukemia homeobox interacting protein 1 or human

73 oteins competitively heterodimerize with pre-B-cell leukemia homeobox-1 (Pbx1).

74 us modified binding of the proadipogenic pre-B-cell leukemia homeobox-1/homeobox 9 complex.

75 The v-Cbl oncogene induces myeloid and B-cell leukemia; however, the mechanism by which transfo

76 in LIC progression and maintenance in T- and B-cell leukemias, (iii) novel epigenetic and age-related

77 degradation of ZFP574 suppressed Myc-driven B cell leukemia in mice, but normal B cells were largely

78 s in vitro, while inducing predominantly pre-B cell leukemias in vivo.

79 ase in childhood megakaryocyte-erythroid and B-cell leukemia in Down syndrome implicates trisomy 21 (

80 Activated ABL oncogenes cause B-cell leukemias in mice and chronic myelogenous leukemi

81 were frequent in patients with other mature B-cell leukemias in which CD20 surface expression is inc

82 gnancies, but are consistently absent in pre-B cell leukemias induced by the chimeric oncoprotein E2a

83 Thus, B cell leukemia-induced inhibition of T cell Akt/mTORC1

84 Drug resistance in B cell leukemia is characterized by the coexpression of

85 the product of a proto-oncogene in acute pre-B-cell leukemia, is a global regulator of embryonic deve

86 2B1-D1 and the parental 12B1 line, but not a B-cell leukemia line, A20.

87 s (IFNs)-alpha/beta and -gamma, whereas, pro-B-cell leukemia lines derived from Emu-ret mice are mark

88 inhibitor, synergized to induce apoptosis in B cell leukemia, lymphoma, and multiple myeloma.

89 such as TNFR-associated factors 2 and 5 and B cell leukemia/lymphoma 10, were readily decreased upon

90 Myeloid cell leukemia sequence 1 (MCL-1) and B cell leukemia/lymphoma 2 (BCL-2) are anti-apoptotic pr

91 The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax

92 4, expression of the anti-apoptotic molecule B cell leukemia/lymphoma 2 (Bcl-2), and enhanced IL-2 pr

93 eukemia 1 (Mcl1) but not other antiapoptotic B cell leukemia/lymphoma 2 (Bcl2) family members.

94 Antiapoptotic B cell leukemia/lymphoma 2 (BCL2) family proteins are ex

95 gher percentage of CD44(v.low) cells express B cell leukemia/lymphoma 2, interleukin-7 receptor, and

96 we show that the transcriptional coregulator B cell leukemia/lymphoma 3 (Bcl3) limits granulopoiesis

97 Instead, the transcription factor B cell leukemia/lymphoma 6 (BCL6) acts in a cell-autonom

98 Here, we identify B cell leukemia/lymphoma 6 (BCL6) as a critical regulato

99 e Kruppel-like transcription factor 6 (KLF6)-B cell leukemia/lymphoma 6 (BCL6) signaling axis as a no

100 Here, we report that B cell leukemia/lymphoma 6 (BCL6), a transcriptional rep

101 at potentiates transcriptional repression by B cell leukemia/lymphoma 6 (BCL6).

102 rus, which encodes v-Abl/p160, induces a pre-B cell leukemia/lymphoma in mice.

103 deletions and mutations in Bcl11b (encoding B cell leukemia/lymphoma-11B) and identify the presence

104 ependence of CG2-expressing leukemias on the B cell leukemia/lymphoma-2 (BCL-2) family of antiapoptot

105 nd truncating temperature-induced changes in B cell leukemia/lymphoma-2 associated X protein alpha an

106 t key repressors of the plasmacytic program, B cell leukemia/lymphoma-6 and paired box gene 5, are re

107 n neutrophils positively correlated with pre-B cell leukemia/lymphoma.

108 CD1d in B1 B cells generating strong B1 ATA B cell leukemia/lymphoma.

109 Using a murine B-cell leukemia/lymphoma (BCL1) model, we showed the dev

110 Upregulation of cyclin D1/B-cell leukemia/lymphoma 1 (CCND1/BCL1) is present in mo

111 ed cyclin D1 expression and progression of a B-cell leukemia/lymphoma 1 tumor in mice by preferential

112 ion and utilizes the adaptor molecule BCL10 (B-cell leukemia/lymphoma 10).

113 sis, we report that the transcription factor B-cell leukemia/lymphoma 11A (BCL11A) is highly expresse

114 In apoptosis, the B-cell leukemia/lymphoma 2 (Bcl-2) family members Bcl-2-

115 labrutinib, zanubrutinib, or ibrutinib) or a B-cell leukemia/lymphoma 2 (BCL2) inhibitor (venetoclax)

116 hese tumors are genetically characterized by B-cell leukemia/lymphoma 2 (BCL2) translocation and muta

117 and tensin homolog, TGFbeta receptor II, and B-cell leukemia/lymphoma 2 -associated X protein.

118 ns, including an enrichment in antiapoptotic B-cell leukemia/lymphoma 2 family protein expression, in

119 parallel decrease in anti-apoptotic protein B-cell leukemia/lymphoma 2 levels.

120 factor profile, with elevated expression of B-cell leukemia/lymphoma 6 (Bcl-6), CXC chemokine recept

121 trast, inhibitory cyclin G2, p27/Cdkn1b, and B-cell leukemia/lymphoma 6 (Bcl6) were sharply down-modu

122 body-dependent cellular cytotoxicity against B-cell leukemia/lymphoma cell lines and primary chronic

123 odel consisting of highly disseminated human B-cell leukemia/lymphoma was developed by i.v. inoculati

124 Using a mouse model of B-cell leukemia/lymphoma, we find that differences in tr

125 The B-cell leukemia/lymphoma-2 (BCL-2) family of proteins go

126 Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is com

127 ), endothelial nitric oxide synthase (eNOS), B-cell leukemia/lymphoma-2 (Bcl-2), and inducible nitric

128 ceptor-associated factor-1 (TRAF-1), TRAF-2, B-cell leukemia/lymphoma-2 (Bcl-2), Bcl-x, A1, and cellu

129 ciated with colorectal cancer formation (eg, B-cell leukemia/lymphoma-2 [Bcl2]) and 1.8% (18/906) wit

130 liminary efficacy of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together with low-

131 Moreover, EGCG suppressed the proteins B-cell leukemia/lymphoma-2 protein (Bcl-2), X-linked inh

132 ular assay for the study of therapy of human B-cell leukemia/lymphoma.

133 Transgenic mice that over-express B cell leukemia/lymphomas (Bcl)-2 in myeloid cells under

134 Thus, precursor B-cell leukemias maintain evolution at the IgH locus at

135 transduced T cells efficiently lysed primary B-cell leukemia, mantle cell lymphoma, and multiple myel

136 In an immunocompetent B cell leukemia model, CAR-PET signal in the spleen pred

137 Notably, in-vivo validation in a Nalm6 B-cell leukemia model confirmed the superior activity of

138 ip in B cell diseases, especially in chronic B cell leukemia, needs to be considered further in regar

139 Hairy cell leukemia (HCL) is a chronic B-cell leukemia noted for an indolent course that ultima

140 ificantly more common in patients with other B-cell leukemias, occurring in five (50%) of 10 patients

141 strated remarkable clinical efficacy against B cell leukemia over the past decade.

142 ecreased, and neurotensin was unexpressed in B cell leukemia patient's cells, as compared with health

143 ) chromosomal translocation of pediatric pre-B cell leukemia produces chimeric oncoprotein E2a-Pbx1,

144 genome-scale shRNA screen for modulators of B-cell leukemia progression in vivo.

145 myelocytic leukemia zinc finger protein, and B-cell leukemia protein 6.

146 ll activating factor, BAFF) developed CD5(+) B-cell leukemia resembling human chronic lymphocytic leu

147 d leukemia, and the t(12;21)(p13;q22) in pre-B-cell leukemia, respectively.

148 We show that loss of Phf6 in B-cell leukemia results in systematic changes in gene ex

149 These anti-pre-B-cell leukemia-specific CTL lysed both unstimulated and

150 w here the generation of autologous anti-pre-B-cell leukemia-specific cytolytic T-cell lines from the

151 ed iNKT cell cytotoxicity against T-cell and B-cell leukemia targets in vitro and iNKT-cell-mediated

152 x1, E2a-Pbx1, is an oncoprotein in human pre-B cell leukemia that strongly suppresses differentiation

153 Pre-B cell leukemia transcription factor 1 (Pbx1) variants a

154 he transcriptional activation of IL10 by pre-B cell leukemia transcription factor-1b and another Hox

155 Here we report that hematopoietic pre-B cell leukemia transcription factor-interacting protein

156 eletion of CDH-implicated genes encoding pre-B cell leukemia transcription factors (Pbx) led to letha

157 Pre-B cell leukemia transcription factors (PBXs) act as cofa

158 otropic viral insertion site (MEIS), and pre-B-cell leukemia transcription factor 1 (PBX) may regulat

159 nhibitors showed that the homeoproteins, pre B-cell leukemia transcription factor 1 (PBX1) and PBX-re

160 CDKIs, we observed a cellular gene, the pre-B-cell leukemia transcription factor 1 (Pbx1) gene, down

161 out mice for one of the candidate genes, pre-B-cell leukemia transcription factor 1 (Pbx1), and ident

162 -binding protein 4) homeobox genes PBX1 (pre-B-cell leukemia transcription factor 1) and MEIS1 (myelo

163 ind to DNA or a key HOX-binding partner, pre-B-cell leukemia transcription factor-1 (PBX1).

164 without altering the genomic DNA and induces B-cell leukemia via genetic deletion of the gene encodin

165 a dramatic increase in the frequency of pro-B cell leukemia was observed in mice with combined heter

166 ng a humanized model of treatment refractory B cell leukemia, we find that infiltration of leukemia c

167 most importantly primary Bcr-Abl-transformed B-cell leukemias were completely eradicated by the alloa

168 T cells from patients with acute or chronic B cell leukemia, which were also metabolically exhausted

169 c B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and l

170 therapy, whereas patients who have precursor B-cell leukemia without other adverse features appear to

171 RT in repetitive killing assays and a canine B cell leukemia xenograft model.

172 -AHPC-mediated cleavage of the antiapoptotic B-cell leukemia XL (Bcl-XL) protein to a proapoptotic 18

173 NF-kappaB-dependent antiapoptotic proteins, B-cell leukemia XL (Bcl-XL), Bcl-2, X-linked inhibitor o